Genomic Subtypes in Choosing Adjuvant Therapy for Breast CancerMarch 15th 2013
Additional insight into the biology of ER-positive breast cancers, particularly the higher risk luminal B cancers, could aid in identifying potential targets and new, effective therapies. And though the majority of triple-negative breast cancers are the “basal-like” subtype, significant proportions are in other subtypes.
Adjuvant Anthracyclines: Time for a Change of Heart?February 18th 2011
As our knowledge of the molecular profiles of breast cancer has increased as a result of moving closer to our goal of individualized therapy, it is clear that we need to re-think our approach to the adjuvant treatment of early-stage breast cancer.
Long-Term Toxicities of Selective Estrogen-Receptor Modulators and Antiaromatase AgentsMay 1st 2003
With the advent of aromataseinhibitor use in the adjuvantsetting, and the inceptionof trials examining their usefor breast cancer prevention, it seemsprudent to evaluate what we know todate about the long-term effects of these agents. Unfortunately, unlike selectiveestrogen-receptor modulators(SERMs)-in particular tamoxifen,which has been used for over 15 yearsin patients with early-stage breast cancer-long-term data on the use of aromataseinhibitors are minimal.
Commentary (Kaklamani/O’Regan): Aromatase Inhibitors as Adjuvant Therapy in Breast CancerMarch 1st 2003
The use of aromatase inhibitorshas increased dramatically inthe past few years as a resultof the emergence of new, more specificagents, such as anastrozole(Arimidex), exemestane (Aromasin),and letrozole (Femara). This class ofagents effectively blocks the peripheralformation of estradiol, decreasingits concentration to less than 10%,while maintaining selectivity.Evaluation of these selective aromataseinhibitors as adjuvant therapyfor early-stage breast cancer wasbased on the findings of trials inmetastatic breast cancer, summarizedby Visvanathan and Davidson, thatdemonstrated the equivalence and,in some cases, superiority of thearomatase inhibitors comparedwith megestrol and tamoxifen,including their superior side-effectprofile.[2-4]